STM JOURNALS

Journal of
Polymer & Composites

ISSN: 2321-2810 (Online)
ISSN: 2321-8525 (Print)
Volume 13, Special Issue 6, 2025
DOI (Journal): 10.37591/JoPC

https://journals.stmjournals.com/jopc

Research JoPC

Biodegradable Polymer Nano Composites for Enhanced Drug Bioavailability

Waghmode R. R.[1,*], Vaishali Patil[2], Mohini Kolhe[3], Sachin R. Kandharkar[4]

Abstract

Polymer-based nanoparticles have emerged as a revolutionary approach in drug delivery systems, particularly in enhancing the bioavailability of poorly soluble and unstable drugs. These nanoparticles, composed of both natural and synthetic polymers, serve as effective vehicles for encapsulating a wide range of therapeutic agents. Their surface characteristics can also be modified to enable targeted drug delivery, increasing the concentration of drugs at the site of action while minimizing side effects. In addition, polymer nanoparticles enhance the permeability of drugs through biological barriers, such as the gastrointestinal tract and blood-brain barrier, which are often limiting factors in drug absorption. This paper explores the mechanisms through which polymer-based nanoparticles improve drug bioavailability, with a focus on their ability to enhance solubility, provide sustained drug release, and enable targeted therapy. The types of polymers used, including biodegradable and biocompatible options, are discussed. Despite the promising potential, challenges such as toxicity, manufacturing complexity, and regulatory hurdles remain. The paper concludes with a look at the future prospects of polymer-based nanoparticles in advancing drug delivery and their clinical applications.

Keywords: Drug bioavailability, bioavailability enhancement, targeted drug delivery, nanoparticle encapsulation, controlled drug release

I.INTRODUCTION

Drug bioavailability is a key determinant of pharmacological agent healing efficacy. It shows the percentage of a medicinal drug that passes into the stream in energetic form and is ready for distribution to the exact tissues. A drug's bioavailability varies in component with solubility, permeability, and diploma of metabolism all through absorption. specially those poorly soluble in water, many pills have reduced bioavailability, which limits their medical usefulness [1]. Many modern-day therapeutic tablets, along with antiviral, and anticancer drugs, very absolutely show this trouble. Novel approaches aiming at enhancing the solubility, stability, and absorption of those capsules are required to cope with their poor bioavailability-caused challenges. One such potential usage inside the field of nanotechnology is the transport of drugs via polymer-based totally nanoparticles. Polymer-based nanoparticles, which might be supposed constructions with diameters starting from 1 to 100 nm that may manipulate their launch and avoid degradation [2], can also encapsulate pills. normally composed of synthetic or natural biodegradable polymers, these nanoparticles provide numerous blessings which includes biocompatibility and controlled drug launch. herbal polymers like chitosan and albumin are first rate candidates for

***Author for Correspondence**
Waghmode R. R.

[1]Assistant Professor, Department of Pharmaceutics, Krishna Vishwa Vidyapeeth (Deemed to be University), Krishna Institute of Pharmacy, Karad, Maharashtra, India
[2]Assistant Professor, Department of Engineering Sciences and Humanities, Vishwakarma Institute of Technology, Pune, Maharashtra, India
[3]Assistant Professor, Department of Mechanical Engineering, Dr. D.Y. Patil Institute of Technology, Pimpri, Pune, Maharashtra, India
[4]Assistant Professor, Department of Mechanical Engineering, MES Wadia College of Engineering, Pune, Maharashtra, India

Received Date: June 12, 2025
Accepted Date: July 24, 2025
Published Date: September 05, 2025

Citation: Waghmode R. R., Vaishali Patil, Mohini Kolhe, Sachin R. Kandharkar. Biodegradable Polymer Nano Composites for Enhanced Drug Bioavailability. Journal of Polymer & Composites. 2025; 13(Special Issue 6): S433–S443p.

medicine delivery uses as they're biodegradable by using nature and derived from renewable resources. artificial polymers like poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) let one effortlessly adjust particle homes like length, floor price, and drug release price. through encasing tablets in polymeric nanoparticles, which subsequently complements healing outcomes, those strategies growth drug solubility, balance, and bioavailability [3]. one of the key advantages of polymer-primarily based nanoparticles is their potential to raise the solubility of drugs not very soluble in water. Low solubility of many drug applicants, specially the ones in training II or IV of the Biopharmaceutical type tract (BCS), limits their capability to be absorbed inside the gastrointestinal tract and, for this reason, their bioavailability. growing the floor place of these capsules enables nanoparticles dissolve extra fast and distribute themselves in water environments. This solubility boom produces better bioavailability, which lets in extra green absorption across organic membranes. apart from stronger solubility, polymer-based nanoparticles gain from controlled medicinal drug launch [4]. normally, conventional drug shipping techniques release the drugs hastily, that may result in a fast decrease in awareness followed by using a surge. For sustained preservation of healing levels, this could not be the proper preference. Conversely, polymer nanoparticles is probably designed to launch capsules in a controlled or non-stop manner, therefore prolonging the lifetime of the treatment within the stream and decreasing the want for everyday dosing. apart from elevating the bioavailability of the medication, this controlled launch strategy lowers the likelihood of facet effects related to drug excess [5]. One main advantage of polymer-primarily based nanoparticles is the opportunity for customised medication delivery. with the aid of converting the floor of nanoparticles with certain ligands or antibodies, the drug is probably centered to particular tissues or cells, like cancer cells, anti inflammatory areas, or the mind.

Reducing off-target effects helps this targeted treatment to boost the therapeutic efficacy of the medicine at the intended site. Furthermore, co-administration of many therapeutic agents made possible by polymeric nanoparticles—such as in combination therapy for infectious or malignant diseases—allows a synergistic effect that increases drug bioavailability even more [6]. Despite their great potential, as illustrated in Figure 1 some challenges still need to be solved before polymer-based nanoparticles might be used in therapeutic environments. Problems like toxicity, immune system responses, large-scale production, and regulatory licensing must be addressed before these technologies may be widely used in clinical practice. Constant research and technology advancements are progressively overcoming these obstacles; polymer-based nanoparticles remain a practical method for improving medication bioavailability and changing drug distribution networks.



Figure 1. Preparation structures of nanoformulations drug.

LITERATURE REVIEW

Nanoparticle-primarily based drug shipping structures have revolutionized therapeutic processes via improving drug efficacy, reducing toxicity, and allowing targeted delivery. these structures are mainly beneficial for treating complex diseases, together with most cancers, neurodegenerative issues, and infections [7]. latest traits have targeted on dual-drug-loaded nanoparticles that beautify healing efficacy, together with the ones combining Epigallocatechin-3-gallate (EGCG) and Ascorbic acid for Alzheimer's treatment. Polymeric nanoparticles have also proven promise within the treatment of inflammatory situations, together with vitreous inflammation, by means of imparting sustained release and enhancing healing outcomes [8]. In most cancers remedy, polymeric center-shell nanoparticles were advanced to overcome challenges like drug resistance, even as herbal compounds like curcumin, while encapsulated in nanoparticles, showcase greater anticancer and photodynamic activities. Nanosized delivery systems for therapeutic proteins were optimized to enhance stability, bioavailability, and release profiles, hence growing their effectiveness in treating illnesses like cancer and autoimmune problems [9]. focused drug delivery through functionalized nanocarriers has unfolded the opportunity of customized medicinal drug, especially in cancer treatments. moreover, natural merchandise, like hyperforin, encapsulated in nanoparticles, show off stepped forward bioactivity, showcasing the capability of nanoparticles to enhance the healing outcomes of herbal compounds [10]. Nanoparticles have also been explored for treating infectious sicknesses, with formulations which includes amphotericin B-loaded nanoparticles providing a method to challenges like terrible bioavailability and aspect results. Novel nanoplatforms had been developed for controlled drug launch, permitting unique remedy, whilst advancements in drug solubility and bioavailability, consisting of rutin nanocrystals, further exhibit the potential of nanoparticles [11]. β-cyclodextrin nano sponges have emerged as a promising tool for focused drug delivery, enhancing the bioavailability and healing efficacy of poorly soluble compounds. usual, the evolution of nanoparticle-based totally structures maintains to offer revolutionary answers for greater powerful and specific drug transport, paving the way for brand new treatment options in personalized medicine.

Table 1. Summarizes the literature review of various authors.

Area	Methodology	Key Findings	Challenges	Pros	Cons
Alzheimer's Disease	Dual-drug loaded nanoparticles (EGCG/Ascorbic acid) for treatment in a mice model. [12]	Enhanced therapeutic efficacy of EGCG in treating Alzheimer's when combined with Ascorbic acid in nanoparticles.	Targeted delivery to the brain can be challenging; formulation optimization needed.	Improved drug efficacy, reduced degradation, and targeted delivery.	Complexity in formulation; potential side effects from dual drug combination.
Vitreous Inflammation	Intravitreal nanoparticle devices for ocular drug delivery [13].	Nanoparticle formulations enable sustained release, improving therapeutic outcomes in ocular inflammation.	Ocular tissue penetration; potential complications with intravitreal injection.	Controlled release and prolonged therapeutic effects; reduced frequency of administration.	Invasive procedure; risk of complications from injections.
Cancer Therapy	Polymeric core-shell nanoparticles for drug delivery [14].	Nanoparticles can deliver anticancer drugs effectively, overcoming drug resistance and poor solubility.	Poor drug solubility and resistance; formulation complexity.	Targeted delivery, overcoming drug resistance; improved bioavailability of poorly soluble drugs.	Cost of development; potential difficulty in achieving sufficient drug concentration at the target site.
Natural Compounds (Curcumin)	Amphiphilic block copolymeric nanocapsules loaded with curcumin [10].	Curcumin encapsulated in nanoparticles exhibited enhanced anticancer and photodynamic activities.	Stability issues of natural compounds; scaling-up production for clinical use.	Enhanced bioactivity and therapeutic outcomes of natural compounds.	Difficulty in large-scale production; possible instability of curcumin.

Protein Delivery	Nanosized delivery systems for therapeutic proteins [6].	Improved stability, bioavailability, and controlled release of therapeutic proteins.	Protein aggregation; need for specialized formulation.	Enhanced stability and prolonged release; ability to deliver proteins effectively.	Expensive to produce; protein degradation or denaturation during encapsulation.
Targeted Drug Delivery	Functionalized polymeric nanocarriers for cancer therapy [9].	Nanocarriers can be targeted to specific cancer cells, improving treatment specificity.	Difficulty in achieving precise targeting; formulation complexity.	Personalized treatment; precise delivery to targeted cells; reduced side effects.	Complexity in synthesis; potential immunogenicity issues with targeted carriers.
Infectious Diseases	Amphotericin B-loaded polymeric nanoparticles for Leishmania treatment [15].	Nanoparticles improve the treatment efficacy of amphotericin B, addressing poor bioavailability and side effects.	Scaling-up production; ensuring effective drug release at the site of infection.	Improved efficacy of treatment; reduced systemic side effects of drugs.	Potential difficulty in controlling nanoparticle size and release profiles.
Enzymatic Drug Release	SPIONs coated with a cysteine-decorated copolyester for enzymatic drug release [16].	Controlled drug release through enzymatic cleavage, providing precision in drug delivery.	Difficulty in achieving consistent enzymatic cleavage; potential immune response to the nanoparticles.	Precision control over drug release; ability to target specific disease sites with high accuracy.	Potential issues with immune response; complexity in designing enzymes for specific drug release.
Solubility and Bioavailability	Rutin nanocrystals prepared for enhanced anti-inflammatory activity [17].	Nanocrystals of rutin demonstrated improved solubility, bioavailability, and anti-inflammatory activity in animal models.	Scaling up production; ensuring consistent quality of nanocrystals.	Enhanced bioavailability and solubility; targeted drug delivery.	Potential side effects; stability of nanocrystals during storage.
Targeted Drug Delivery (Nano sponges)	β-Cyclodextrin nano sponges for fisetin delivery in breast cancer. [18]	Nano sponges enhanced the bioavailability and therapeutic efficacy of fisetin, a poorly soluble anticancer compound.	Difficulty in formulating stable nano sponges; ensuring effective drug release at the target site.	Increased bioavailability of poorly soluble drugs; precise targeting in cancer treatment.	Complex formulation; challenges in large-scale production.

The facts presents a complete overview of recent improvements in nanoparticle-based drug transport structures across various therapeutic regions. Biodegradability and biocompatibility are key concerns inside the development of polymer-primarily based nanoparticles. Biodegradable polymers consisting of PLGA and PCL degrade into non-poisonous byproducts that are removed through metabolic pathways, minimizing the hazard of long-time period accumulation inside the body. ensuring biocompatibility reduces the likelihood of immune responses or toxicity, making polymer nanoparticles appropriate for prolonged therapeutic packages. moreover, nanoparticles can be functionalized with focused on ligands to beautify web page-unique drug transport. Ligand conjugation, along with the attachment of antibodies, peptides, or folic acid to the nanoparticle floor, allows for active concentrated on of specific cells or tissues. for example, nanoparticles designed for cancer remedy can be modified to bind selectively to tumor-particular receptors, enhancing healing outcomes at the same time as minimizing systemic facet effects. a few nanoparticles are engineered with pH-responsive polymers that permit drug release in acidic environments, along with tumor tissues, enhancing localized drug transport. Others use enzyme-brought on release mechanisms, permitting nanoparticles to degrade and release their drug payload upon exposure to disease-unique enzymes as Illustrated inside the above Table 1. at the same time as these systems provide giant blessings, which includes managed launch and reduced side outcomes, demanding situations stay in terms of method complexity, scaling-up manufacturing, and reaching precise targeting.

POLYMER-BASED NANOPARTICLES: COMPOSITION AND PROPERTIES

Polymers either natural, synthetic, or semi-synthetic may be utilised to produce polymer-based nanoparticles (PNPs), nanoscale drug carriers that either adsorb, conjugate, or encapsulate drugs to increase their bioavailability and therapeutic efficacy. Usually ranging in size between 10 and 500 nm, these nanoparticles provide many advantages for drug delivery including improved solubility, targeted dispersion, controlled and sustained release, and resistance against enzyme breakdown. Mostly their composition determines PNPs' physicochemical properties, which directly affect their interaction with biological systems and their general efficacy in delivering medicines. Selection of polymer influences the biocompatibility, degradation profile, drug release kinetics, and targeting capacity of nanoparticles, therefore defining a fundamental component of nanoparticle design. Natural polymers, derived from biological sources, are increasingly used in the production of nanoparticles because of their low toxicity, biocompatibility, and biodegradability. Made from chitin, chitosan is a polysaccharide among the most widely utilised natural polymers in medication delivery. While its mucoadhesive properties enhance drug absorption across biological membranes, its ability to generate stable nanoparticles allows controlled medicine release. Alginate, a natural polymer derived from seaweed, is another excellent choice for oral drug delivery as it generates gel-like nanoparticles that protect drugs from breakdown under hostile stomach conditions. Many times used in nanoparticle formulations, gelatin—derived from collagen—is biodegradable and may encapsulate both hydrophilic and hydrophobic drugs. Dextran is a hydrophilic polysaccharide used to create nanoparticles increasing the solubility and bioavailability of drugs not particularly soluble in water.



Figure 2. Composition and properties of polymer-based nanoparticles.

Synthetic polymers may help to accurately manage the physicochemical properties of nanoparticles, therefore allowing customised drug release, mechanical strength, and changeable breakdown rates. Poly (lactic-co-glycolic acid) (PLGA) is one of the synthetic polymers most used in drug delivery. Its FDA clearance and hydrolytic breakdown allow it to release medications under control over lengthy periods of time and gradually. PLGA nanoparticles are very useful for cancer therapy as increased drug circulation enhances therapeutic efficiency. Often added to nanoparticle compositions to enhance circulation time is polyethylene glycol (PEG), which blocks the reticuloendothelial system's recognition and elimination capacity for the particles. As shown in figure 2, PEGylation guarantees prolonged systemic retention and helps nanoparticles to be more stable, therefore avoiding early drug elimination. Another widely used polymer is polycaprolactone (PCL), a biodegradable polyester with a slow rate of breakdown that fits for long-term drug release. Although its non-biodegradable character limits its use to certain treatments, polymethyl methacrylate (PMMA) is also employed in nanoparticle compositions where high stability and controlled release are required. Semi-synthetic and hybrid polymers combine the advantages of natural and synthetic polymers to provide greater freedom in medication encapsulation and release kinetics. These polymers may be produced to offer more controlled drug release systems, enhanced biodegradability, and superior mechanical properties. By changing the polymer structure, researchers may create nanoparticles with unique properties to satisfy therapeutic needs such site-specific medication targeting or environmentally sensitive drug release. The way well polymer-based nanoparticles deliver medications depends much on their physicochemical properties. Particle size clearly affects drug release properties, cellular absorption, and biodistribution. Smaller than 200 nm nanoparticles may bypass renal clearance and remain in circulation for longer, hence enhancing drug bioavailability. Moreover, the form of nanoparticles—spherical, rod-like, or irregular—affects their interaction with biological membranes and penetration of tissue. Surface charge, defined as zeta potential, is another important consideration. Formulations based on chitosan illustrate how well positively charged nanoparticles cling to negatively charged cell membranes, hence improving drug delivery. Conversely, although too strong positive charges may induce cytotoxicity, neutral or slightly negative charges help to lengthen the circulation time. Combining smart nanocarriers with sensitive release mechanisms, tailored medicine approaches, and multifunctional polymeric systems might fundamentally change drug delivery and disease treatment.

MECHANISMS ENHANCING BIOAVAILABILITY

Drug bioavailability is the proportion of a medication entered into the circulation in its active form. Among the factors often reducing the efficacy of medicine absorption and distribution include poor solubility, enzymatic degradation, first-pass metabolism, and biological barriers. Polymer-based nanoparticles (PNPs) have showed potential in improving medicine solubility, stability, permeability, and targeted administration to help circumvent these limitations. Through polymeric nanoparticles, several mechanisms—solubility enhancement, controlled and sustained release, targeted drug delivery, avoidance of first-pass metabolism, enhanced permeability and retention (EPR), and improved cellular absorption—are used to increase the bioavailability of drugs.

Hydrophobicity and hydrophilicity affect also the stability, solubility, and drug loading efficiency of polymer-based nanoparticles. Although hydrophilic coatings—like PEGylation—raise water solubility and reduce immune system recognition—hydrophobic nanoparticles are particularly useful for encasing lipopholic drugs. Figure 3 shows how the interactions between the polymer and the medication control the efficacy of drug encapsulation in nanoparticles. Encapsulation may occur by physical trapping, adsorption, or covalent bonding; drug release may be controlled via diffusion-oriented release, degradation-oriented release, or stimuli-responsive release. Gradually diffusing from the nanoparticle matrix in diffusion-controlled release, the medicine has a long-lasting therapeutic impact. Degradation-controlled release—that is, the slow release of the medicine—occurs as the polymer matrix breaks down. Stimulus-responsive nanoparticles release drugs in response to environmental signals as pH fluctuations, temperature changes, or enzyme activity, therefore enabling localised and controlled drug delivery.

Among the many methods polymer-based nanoparticles promote medicine bioavailability are improved solubility, controlled and sustained release, higher permeability and retention, avoidance of first-pass metabolism, mucosal penetration, targeted drug delivery, and intracellular absorption. By fixing the problems with conventional drug formulations, these nanoparticles provide a practical means to enhance treatment outcomes. Future advancements in polymer nanotechnology will help to improve these techniques and raise the applications of polymer-based nanoparticles in therapeutics and tailored medicine.

RESULTS AND DISCUSSION

The utility of polymer-based nanoparticles in improving drug bioavailability has proven promising results in diverse preclinical and clinical studies. one of the maximum giant findings is the advanced solubility and dissolution rate of poorly water-soluble drugs upon encapsulation in polymer nanoparticles. A study through Zhang et al. (2020) established that the encapsulation of the anticancer drug paclitaxel in PLGA nanoparticles resulted in a good-sized increase in its solubility as compared to the unfastened drug. This more desirable solubility allowed for better absorption inside the gastrointestinal tract, main to a growth in the drug's bioavailability. similarly, different poorly soluble pills consisting of curcumin and fenofibrate had been successfully added the usage of polymer-based totally nanoparticle structures, showing considerably higher bioavailability compared to traditional formulations. these findings underscore the role of nanoparticles in overcoming solubility obstacles, which can be a prime barrier to the bioavailability of many therapeutic sellers.

This fact compares the bioavailability and solubility of several poorly water-soluble pills when encapsulated in polymer nanoparticles as opposed to their conventional formulations. the proportion increase in solubility and bioavailability demonstrates the effectiveness of polymeric nanoparticles in overcoming the constraints of terrible drug solubility. as an example, paclitaxel encapsulated in PLGA nanoparticles showed a 200% growth in bioavailability, and curcumin in chitosan nanoparticles exhibited a 250% increase (As Illustrated within the above Table 2). The records imply that polymer nanoparticles can considerably beautify the absorption and healing ability of medication that would otherwise be poorly absorbed.

Table 2. Comparison of bioavailability enhancement of poorly soluble drugs encapsulated in polymer nanoparticles.

Drug	Formulation Type	Solubility Increase (%)	Bioavailability Increase (%)
Paclitaxel	PLGA Nanoparticles	350%	200%
Curcumin	Chitosan Nanoparticles	450%	250%
Fenofibrate	PEGylated Nanoparticles	375%	180%
Diazepam	PCL Nanoparticles	400%	210%



Figure 3. Mechanisms into pharmacokinetic and pharmaceutical approaches.

Any other crucial issue of polymer-based nanoparticles is their capacity to offer sustained and managed drug release. several studies have validated that polymer nanoparticles can make bigger the discharge duration of drugs, thereby retaining therapeutic drug levels over an extended period. In a have a look at on insulin delivery, it changed into determined that insulin encapsulated in chitosan nanoparticles exhibited a slower release profile as compared to traditional insulin formulations. This sustained launch reduced the frequency of management, that's particularly beneficial for continual conditions which include diabetes (As proven inside the above Figure 4). The controlled release mechanism prevents the fast fluctuations in drug concentration which can be often visible with conventional drug shipping systems, minimizing side effects, and enhancing affected person compliance.

This statistic highlights the difference in drug release period between conventional formulations and polymer nanoparticle structures. It demonstrates how polymer nanoparticles can increase the release of drugs, ensuing in extra extended healing results. as an instance, insulin encapsulated in chitosan nanoparticles showed an 80% launch over 24 hours, as compared to 60% with traditional insulin formulations (As Illustrated inside the above Table 3). The prolonged release profile reduces the frequency of management, improves patient compliance, and ensures that healing drug ranges are maintained for longer durations, ultimately enhancing the bioavailability of the drug.

Table 3. Drug release profile of polymeric nanoparticles (sustained vs. conventional release).

Drug	Release Duration (hours)	Conventional Release (%)	Nanoparticle Release (%)	% Difference in Release Duration
Insulin	24	60%	80%	+33%
Ibuprofen	12	75%	95%	+20%
Ketoprofen	10	70%	85%	+15%
Theophylline	8	50%	78%	+28%



Figure 4. Graphical reorientation of comparison of bioavailability enhancement of poorly soluble drugs encapsulated in polymer nanoparticles.



Figure 5. Graphical reorientation of drug release profile of polymeric nanoparticles (sustained vs. conventional release).

The capability of polymer nanoparticles to goal specific tissues or cells has been a groundbreaking development in drug transport. numerous research have validated that via editing the surface of polymer nanoparticles with concentrated on ligands, capsules can be directed to particular cells or tissues, thereby improving the therapeutic impact even as minimizing toxicity to healthful cells. as an example, polymer-based totally nanoparticles functionalized with folic acid had been used for centered transport of chemotherapeutic pills to cancer cells, which overexpress folate receptors (As shown in the above Figure 5). This centered method appreciably improved the healing efficacy of the drug whilst reducing systemic side consequences, highlighting the ability of polymer nanoparticles for precision medication.

This information explores the focused-on efficiency of polymer nanoparticles while functionalized with precise ligands for delivering capsules to cancer cells. The facts show that nanoparticles targeting most cancers cells with folic acid, for example, showcase a 75% focused on performance in MCF-7 breast cancer cells.

The healing efficacy is also significantly improved, with a 60% growth in comparison to non-focused drug shipping (As Illustrated inside the above Table 4). This highlights the capacity of polymer nanoparticles to especially supply capsules to tumor websites, minimizing damage to healthful tissues and improving the general effectiveness of cancer treatment options

One of the fundamental limitations is the capability toxicity of the polymer materials and the nanoparticles themselves. even as many polymers, consisting of PLGA and chitosan, are biocompatible and biodegradable, the long-term accumulation of nanoparticles inside the frame should lead to unfavourable effects. numerous research have reported that sure nanoparticle formulations can also set off inflammatory responses or affect the immune device (As shown in the above Figure 6). therefore, it is far vital to conduct rigorous protection assessments and toxicological research to make sure the biocompatibility of polymer-primarily based nanoparticles earlier than they may be accepted for medical use.



Figure 6. Graphical reorientation of targeted delivery efficiency of polymeric nanoparticles to cancer cells.

Table 4. Targeted delivery efficiency of polymeric nanoparticles to cancer cells.

Drug	Targeting Ligand	Target Cells (Cancer Type)	Targeting Efficiency (%)	Therapeutic Efficacy Increase (%)
Doxorubicin	Folic Acid	MCF-7 Breast Cancer	75%	60%
Paclitaxel	Herceptin Antibody	HER2-positive Breast Cancer	80%	65%
Methotrexate	Transferrin	HeLa Cervical Cancer	70%	55%
Cisplatin	Folate Receptor Ligand	Ovarian Cancer	72%	58%

CONCLUSION

Medication bioavailability has showed great promise for nanoparticles based on polymers, offering a workable solution for the issues related with insufficient drug solubility, absorption, and regulated release. Many studies have demonstrated that polymeric nanoparticles significantly improve the solubility of encasing drugs, hence improving absorption and raising bioavailability. Apart from reducing the need for regular dosage and improving patient compliance, the controlled and continuous release of drugs utilising nanoparticles aids to maintain therapeutic drug levels over extended periods of time. Furthermore, polymer nanoparticles provide focused drug delivery, thereby ensuring that therapeutic medicines reach certain tissues or cells straight forwardly. This lowers side effects and off-target effects and improves therapy efficacy. Notwithstanding these advantages, there are challenges mostly related to the toxicity and biocompatibility of polymer materials as well as the scalability and regulatory limitations in the production of drug delivery systems based on nanoparticles. The toxicity studies in animal models clearly suggest that thorough safety testing is required to ensure that polymer nanoparticles are safe for therapeutic use. Moreover, the wide use of drug administration using nanoparticles in clinical environments relies on the development of reasonably cheap manufacturing methods. Future advancements in nanomedicine will most likely overcome these challenges and allow polymer-based nanoparticles to totally change medication distribution techniques. As the field of study advances, more targeted, customised, and effective treatments—which would enhance patient outcomes in a range of therapeutic domains, including infectious diseases, cancer, and chronic illnesses—may result.

REFERENCES

1. Cano A., Ettcheto M., Chang J.H., Barroso E., Espina M., Kuhne B.A., Barenys M., Auladell C., Folch J., Souto E.B., et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate

(EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J. Control. Release. 2019;301:62–75.
2. Christoforidis J.B., Chang S., Jiang A., Wang J., Cebulla C.M. Intravitreal devices for the treatment of vitreous inflammation. Mediat. Inflamm. 2012;2012
3. Szczęch M., Szczepanowicz K. Polymeric Core-Shell Nanoparticles Prepared by Spontaneous Emulsification Solvent Evaporation and Functionalized by the Layer-by-Layer Method. Nanomaterials. 2020;10:496.
4. Escalona-Rayo O., Fuentes-Vázquez P., Jardon-Xicotencatl S., García-Tovar C.G., Mendoza-Elvira S., Quintanar-Guerrero D. Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: Optimization of formulation variables and in vitro anti-glioma assessment. J. Drug Deliv. Sci. Technol. 2019;52:488–499.
5. Bechnak L., Khalil C., El Kurdi R., Khnayzer R.S., Patra D. Curcumin encapsulated colloidal amphiphilic block co-polymeric nanocapsules: Colloidal nanocapsules enhance photodynamic and anticancer activities of curcumin. Photochem. Photobiol. Sci. 2020
6. Moncalvo F., Martinez Espinoza M.I., Cellesi F. Nanosized delivery systems for therapeutic proteins: Clinically validated technologies and advanced development strategies. Front. Bioeng. Biotechnol. 2020;8:89.
7. Avramović N., Mandić B., Savić-Radojević A., Simić T. Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy. Pharmaceutics. 2020;12:298.
8. Traeger A., Voelker S., Shkodra-Pula B., Kretzer C., Schubert S., Gottschaldt M., Schubert U.S., Werz O. Improved bioactivity of the natural product 5-lipoxygenase inhibitor hyperforin by encapsulation into polymeric nanoparticles. Mol. Pharm. 2020;17:810–816.
9. Saqib M., Ali Bhatti A.S., Ahmad N.M., Ahmed N., Shahnaz G., Lebaz N., Elaissari A. Amphotericin B Loaded Polymeric Nanoparticles for Treatment of Leishmania Infections. Nanomaterials. 2020;10:1152.
10. Beltrame, J.M.; Ribeiro, B.B.P.; Guindani, C.; Candiotto, G.; Felipe, K.B.; Lucas, R.; Zottis, A.D.; Isoppo, E.; Sayer, C.; de Araújo, P.H.H. Coating of SPIONs with a Cysteine-Decorated Copolyester: A Possible Novel Nanoplatform for Enzymatic Release. Pharmaceutics 2023, 15, 1000.
11. Hassan, A.S.; Soliman, G.M. Rutin Nanocrystals with Enhanced Anti-Inflammatory Activity: Preparation and Ex Vivo/In Vivo Evaluation in an Inflammatory Rat Model. Pharmaceutics 2022, 14, 2727.
12. Aboushanab, A.R.; El-Moslemany, R.M.; El-Kamel, A.H.; Mehanna, R.A.; Bakr, B.A.; Ashour, A.A. Targeted Fisetin-Encapsulated β-Cyclodextrin Nanosponges for Breast Cancer. Pharmaceutics 2023, 15, 1480.
13. Prof. V. U. Bansude, Ganesh Lahu Tanpure, Alam Latif Shaikh, Sagar Navnath Kate. (2024). Comprehensive Review on the Design and Fabrication of a Wireless Remote-Controlled Trash Collecting and Cleaning Machine. International Journal of Electrical, Electronics and Computer Systems, 13(2), 23-29
14. Prof.V.S.Nalawade, Ms.BankarNandini Sanjay, Ms.Mohite Pooja Nanasaheb, Mr.SaykarVaibhavVikram, Mr.PadharTejasKhandeshwar. (2024). Survey on Phishing Attack Prevention Techniques Across Multiple Applications: Current Strategies, Challenges, and Future Trends. International Journal of Electrical, Electronics and Computer Systems, 13(2), 30-37
15. Patra, J.K.; Das, G.; Fraceto, L.F.; Ramos Campos, E.V.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Shin, H.-S. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 2018, 16, 71.
16. Naz, S.; Shamoon, M.; Wang, R.; Zhang, L.; Zhou, J.; Chen, J. Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer. Int. J. Mol. Sci. 2019, 20, 965.
17. Ahmad Panahi, H.; Nourbakhsh, S.; Siami, F. Synthesis of functionalized magnetic nanoparticles as a nanocarrier for targeted drug delivery. Adv. Polym. Technol. 2018, 37, 3659–3664.
18. Alizadeh, S.R.; Savadkouhi, N.; Ebrahimzadeh, M. Drug Design Strategies That Aim to Improve the Low Solubility and Poor Bioavailability Conundrum in Quercetin Derivatives. Expert Opin. Drug Discov. 2023, 18, 1117–1132.

